| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
|
N Engl J Med
|
2006
|
25.67
|
|
2
|
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
|
N Engl J Med
|
2007
|
10.06
|
|
3
|
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
|
Lancet Oncol
|
2009
|
8.46
|
|
4
|
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
|
J Clin Oncol
|
2008
|
5.04
|
|
5
|
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
J Clin Oncol
|
2008
|
4.82
|
|
6
|
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
|
J Clin Oncol
|
2007
|
3.37
|
|
7
|
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
|
J Clin Oncol
|
2011
|
3.31
|
|
8
|
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
|
J Clin Oncol
|
2010
|
2.41
|
|
9
|
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.
|
Clin Cancer Res
|
2012
|
2.02
|
|
10
|
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.
|
Clin Cancer Res
|
2010
|
1.95
|
|
11
|
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
|
J Clin Oncol
|
2007
|
1.91
|
|
12
|
Effects of food on the relative bioavailability of lapatinib in cancer patients.
|
J Clin Oncol
|
2009
|
1.79
|
|
13
|
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
|
J Clin Oncol
|
2007
|
1.66
|
|
14
|
Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.
|
Clin Cancer Res
|
2012
|
1.56
|
|
15
|
Increased recurrences using intensity-modulated radiation therapy in the postoperative setting.
|
Am J Clin Oncol
|
2010
|
1.52
|
|
16
|
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).
|
J Thorac Oncol
|
2007
|
1.39
|
|
17
|
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
|
Cancer
|
2012
|
1.32
|
|
18
|
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
|
J Clin Oncol
|
2009
|
1.30
|
|
19
|
Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers.
|
J Clin Oncol
|
2009
|
1.28
|
|
20
|
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin.
|
J Thorac Oncol
|
2009
|
1.14
|
|
21
|
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.
|
J Clin Oncol
|
2007
|
1.14
|
|
22
|
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?
|
J Clin Oncol
|
2012
|
1.11
|
|
23
|
The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.
|
Clin Adv Hematol Oncol
|
2008
|
1.06
|
|
24
|
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
1.06
|
|
25
|
Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program.
|
J Rheumatol
|
2013
|
1.04
|
|
26
|
Targeting signal transduction pathways in colorectal cancer--more than skin deep.
|
J Clin Oncol
|
2005
|
1.04
|
|
27
|
Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.
|
Expert Rev Anticancer Ther
|
2006
|
0.98
|
|
28
|
Impact of neck dissection on long-term feeding tube dependence in patients with head and neck cancer treated with primary radiation or chemoradiation.
|
Head Neck
|
2010
|
0.94
|
|
29
|
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
|
Head Neck
|
2005
|
0.92
|
|
30
|
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
|
Head Neck
|
2009
|
0.92
|
|
31
|
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2010
|
0.92
|
|
32
|
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.
|
Cancer Res
|
2010
|
0.92
|
|
33
|
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer.
|
Biologics
|
2010
|
0.91
|
|
34
|
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
|
Invest New Drugs
|
2012
|
0.89
|
|
35
|
EGFR-targeting monoclonal antibodies in head and neck cancer.
|
Curr Cancer Drug Targets
|
2006
|
0.88
|
|
36
|
EGFR-targeting monoclonal antibodies in head and neck cancer.
|
Curr Cancer Drug Targets
|
2007
|
0.87
|
|
37
|
Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma.
|
Clin Cancer Res
|
2010
|
0.87
|
|
38
|
An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.
|
Clin Colorectal Cancer
|
2009
|
0.87
|
|
39
|
Unexpected dementia following prophylactic cranial irradiation for small cell lung cancer: case report.
|
J Neurooncol
|
2007
|
0.86
|
|
40
|
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
|
Cancer Chemother Pharmacol
|
2010
|
0.85
|
|
41
|
Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents.
|
J Immunother
|
2015
|
0.83
|
|
42
|
A Web-based communication aid for patients with cancer: the CONNECT Study.
|
Cancer
|
2013
|
0.81
|
|
43
|
A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2006
|
0.79
|
|
44
|
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
|
J Thorac Oncol
|
2014
|
0.79
|
|
45
|
Clinical application of EGFR inhibitors in head and neck squamous cell cancer.
|
Cancer Treat Res
|
2008
|
0.78
|
|
46
|
Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-Small Cell Lung Cancer Receiving Sequential Treatment.
|
Am J Clin Oncol
|
2016
|
0.78
|
|
47
|
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.
|
Invest New Drugs
|
2014
|
0.77
|
|
48
|
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
|
Invest New Drugs
|
2014
|
0.76
|
|
49
|
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy.
|
J Thorac Oncol
|
2008
|
0.76
|
|
50
|
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.
|
Anticancer Drugs
|
2015
|
0.75
|
|
51
|
New agents in the treatment for malignancies of the salivary and thyroid glands.
|
Hematol Oncol Clin North Am
|
2008
|
0.75
|
|
52
|
A Single-institution Comparison of Cetuximab, Carboplatin, and Paclitaxel Induction Chemotherapy Followed by Chemoradiation (CRT) Versus CRT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN).
|
Am J Clin Oncol
|
2016
|
0.75
|
|
53
|
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.
|
Cancer Chemother Pharmacol
|
2015
|
0.75
|
|
54
|
The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.75
|
|
55
|
EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
|
Curr Oncol Rep
|
2008
|
0.75
|
|
56
|
Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group.
|
Cancer Invest
|
2004
|
0.75
|